Quick Dispatch:
Your surmount 5 tirzepatide ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount 5 tirzepatide ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction ships.
Need Help?
Questions about surmount 5 tirzepatide ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount 5 tirzepatide ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction in your area.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
21.38
In the SURMOUNT-5 trial, Zepbound (tirzepatide) achieved a 20.2% average weight loss over 72 weeks, surpassing Wegovy (semaglutide)'s 13.7%. Additionally, 64.6% of Zepbound users lost at least 15% of their body weight,
22.10
Zepbound Shows Superior Weight Loss Compared to Wegovy in SURMOUNT-5 Trial
25.66
Presented at #ECO2025: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results:
25.30
SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial
21.77
Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial
26.21
Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5
21.92
